DOI QR코드

DOI QR Code

DEP Domain Containing 1 is a Novel Diagnostic Marker and Prognostic Predictor for Hepatocellular Carcinoma

  • Yuan, Sheng-Guang (Laboratory of Hepatobiliary and Pancreatic Surgery, Affiliated Hospital of Guilin Medical University) ;
  • Liao, Wei-Jia (Laboratory of Hepatobiliary and Pancreatic Surgery, Affiliated Hospital of Guilin Medical University) ;
  • Yang, Jian-Jun (Laboratory of Hepatobiliary and Pancreatic Surgery, Affiliated Hospital of Guilin Medical University) ;
  • Huang, Guo-Jin (Guangxi Key Laboratory of Molecular Medicine in Liver Injury and Repair) ;
  • Huang, Zhao-Quan (Guangxi Key Laboratory of Molecular Medicine in Liver Injury and Repair)
  • Published : 2015.01.22

Abstract

Background: This study was conducted to determine DEPDC1 expression in hepatocelluar carcinomas (HCCs) and to reveal its potential role in diagnosis and prognosis of affected patients. Materials and Methods: DEPDC1 expression at the mRNA level was detected by quantitative real-time PCR (qRT-PCR) in 205 cases of HCC and paired adjacent normal liver tissues, and by semi-quantitative RT-PCR in 20 cases. Survival curves were obtained by using Kaplan-Meier method and Log-rank test. Independent predictors associated with regard to disease free survival (DFS) and overall survival (OS) were identified using the Cox proportional hazard model. Results: High DEPDC1 mRNA levels were detected in 144 out of 205 cases (70.24%) of HCC, significantly associated with clinicopathological parameters, including tumor size (${\geq}4cm$), alpha-fetoprotein (${\geq}100ng/ml$), B-C of BCLC stage and recurrence. Kaplan-Meier survival analysis revealed that HCC patients with high DEPDC1 expression had poor OS and DFS. Multivariate analysis demonstrated that high DEPDC1 expression was an independent predictor for OS (HR=1.651; 95% 95%CI, 1.041-2.617; p=0.033) and DFS (HR=1.583; 95%CI, 1.01-2.483; p=0.045). Conclusions: Our results indicate DEPDC1 might be a novel diagnostic marker and an independent prognostic predictor for HCC patients.

Acknowledgement

Supported by : National Natural Science Foundation of China

References

  1. Ballon DR, Flanary PL, Gladue DP, et al (2006). DEP-domain-mediated regulation of gpcr signaling responses. Cell, 126, 1079-93. https://doi.org/10.1016/j.cell.2006.07.030
  2. Cheng CH, Lee CF, Wu TH, et al (2011). Evaluation of the new AJCC staging system for resectable hepatocellular carcinoma. World J Surg Oncol, 9, 114. https://doi.org/10.1186/1477-7819-9-114
  3. Ercolani G, Grazi GL, Ravaioli M, et al (2003). Liver resection for hepatocellular carcinoma on cirrhosis: univariate and multivariate analysis of risk factors for intrahepatic recurrence. Ann Surg, 237, 536-43.
  4. Fazeli Z, Pourhoseingholi MA, Vahedi M, et al (2012). Burden of hepatocellular carcinoma in Asia. Asian Pac J Cancer Prev, 13, 5955-8. https://doi.org/10.7314/APJCP.2012.13.12.5955
  5. Forner A, Llovet JM, Bruix J (2012). Hepatocellular carcinoma. Lancet, 379, 1245-55. https://doi.org/10.1016/S0140-6736(11)61347-0
  6. Harada Y, Kanehira M, Fujisawa Y, et al (2010). Cell-permeable peptide DEPDC1-ZNF224 interferes with transcriptional repression and oncogenicity in bladder cancer cells. Cancer Res, 70, 5829-39. https://doi.org/10.1158/0008-5472.CAN-10-0255
  7. Ji D, Lu Z-T, Li Y-Q, et al (2014). MACC1 Expression Correlates with PFKFB2 and Survival in Hepatocellular Carcinoma. Asian Pac J Cancer Prev, 15, 999-1003. https://doi.org/10.7314/APJCP.2014.15.2.999
  8. Kanehira M, Harada Y, Takata R, et al (2007). Involvement of upregulation of DEPDC1 (DEP domain containing 1) in bladder carcinogenesis. Oncogene, 26, 6448-55. https://doi.org/10.1038/sj.onc.1210466
  9. Kassambara A, Schoenhals M, Moreaux J, et al (2013). Inhibition of DEPDC1A, a bad prognostic marker in multiple myeloma, delays growth and induces mature plasma cell markers in malignant plasma cells. PLoS One, 8, 62752. https://doi.org/10.1371/journal.pone.0062752
  10. Kharrat A, Millevoi S, Baraldi E, et al (1998). Conformational stability studies of the pleckstrin DEP domain: definition of the domain boundaries. Biochim Biophys Acta, 1385, 157-64. https://doi.org/10.1016/S0167-4838(98)00041-7
  11. Kobayashi A, Kawasaki S, Miyagawa S, et al (2006). Results of 404 hepatic resections including 80 repeat hepatectomies for hepatocellular carcinoma. Hepatogastroenterol, 53, 736-41.
  12. Kretschmer C, Sterner-Kock A, Siedentopf F, et al (2011). Identification of early molecular markers for breast cancer. Mol Cancer, 10, 15. https://doi.org/10.1186/1476-4598-10-15
  13. Liao W, Liu W, Yuan Q, et al (2013). Silencing of DLGAP5 by siRNA significantly inhibits the proliferation and invasion of hepatocellular carcinoma cells. PLoS One, 8, 80789. https://doi.org/10.1371/journal.pone.0080789
  14. Obara W, Ohsawa R, Kanehira M, et al (2012). Cancer peptide vaccine therapy developed from oncoantigens identified through genome-wide expression profile analysis for bladder cancer. Jpn J Clin Oncol, 42, 591-600. https://doi.org/10.1093/jjco/hys069
  15. Okayama H, Kohno T, Ishii Y, et al (2012). Identification of genes upregulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas. Cancer Res, 72, 100-11.
  16. Peng SY, Chen WJ, Lai PL, et al (2004). High alpha-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and beta-catenin mutations. Int J Cancer, 112, 44-50. https://doi.org/10.1002/ijc.20279
  17. Sendoel A, Maida S, Zheng X, et al (2014). DEPDC1/LET-99 participates in an evolutionarily conserved pathway for anti-tubulin drug-induced apoptosis. Nat Cell Biol, 16, 812-20. https://doi.org/10.1038/ncb3010
  18. Sokol S (2000). A role for Wnts in morpho-genesis and tissue polarity. Nat Cell Biol, 2, 124-5. https://doi.org/10.1038/35017136
  19. Tandon P, Garcia-Tsao G (2009). Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver Int, 29, 502-10. https://doi.org/10.1111/j.1478-3231.2008.01957.x
  20. Tralhao JG, Dagher I, Lino T, et al (2007). Treatment of tumour recurrence after resection of hepatocellular carcinoma. Analysis of 97 consecutive patients. Eur J Surg Oncol, 33, 746-51. https://doi.org/10.1016/j.ejso.2006.11.015
  21. Wang T, Hu HS, Feng YX, et al (2010). Characterisation of a novel cell line (CSQT-2) with high metastatic activity derived from portal vein tumour thrombus of hepatocellular carcinoma. Br J Cancer, 102, 1618-26. https://doi.org/10.1038/sj.bjc.6605689

Cited by

  1. Validation and ranking of seven staging systems of hepatocellular carcinoma vol.14, pp.1, 2017, https://doi.org/10.3892/ol.2017.6222
  2. Determining consistent prognostic biomarkers of overall survival and vascular invasion in hepatocellular carcinoma vol.5, pp.12, 2018, https://doi.org/10.1098/rsos.181006